Zhaohong Geng

Dr. Zhaohong Geng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Global Medical Genetics
Verified
Journal Article
Open access
PDF file
EQEskandar Qaed
Eskandar Qaed
BABandar Al-Hamyari
Bandar Al-Hamyari
AAAhmed Al-Maamari
Ahmed Al-Maamari
AQAbdullah Qaid
Abdullah Qaid
HAHaneen Alademy
Haneen Alademy
XMXiaodong Ma
Xiaodong Ma
Background Cancer remains a critical global health challenge and a leading cause of mortality. Flavonoids found in fruits and vegetables have gained attention for their potential anti-cancer properties. Fisetin, abundantly present in strawberries, apples, onions, and other plant sources, has emerged as a promising candidate for cancer prevention. Epidemiological studies linking a diet rich in these foods to lower cancer risk have sparked extensive research on fisetin’s efficacy. Objective This review aims to comprehensively explore the molecular mechanisms of fisetin's anticancer properties and investigate its potential synergistic effects with other anticancer drugs. Furthermore, the review examines the therapeutic and preventive effects of fisetin against various cancers. Methods A systematic analysis of the available scientific literature was conducted, including research articles, clinical trials, and review papers related to fisetin’s anticancer properties. Reputable databases were searched, and selected studies were critically evaluated to extract essential information on fisetin’s mechanisms of action and its interactions with other anticancer drugs. Results Preclinical trials have demonstrated that fisetin inhibits cancer cell growth through mechanisms such as cell cycle alteration, induction of apoptosis, and activation of the autophagy signaling pathway. Additionally, fisetin reduces reactive oxygen species levels, contributing to its overall anticancer potential. Investigation of its synergistic effects with other anticancer drugs suggests potential for combination therapies. Conclusion Fisetin, a bioactive flavonoid abundant in fruits and vegetables, exhibits promising anticancer properties through multiple mechanisms of action. Preclinical trials provide a foundation for further exploration in human clinical trials. Understanding fisetin’s molecular mechanisms is vital for developing novel, safe, and effective cancer prevention and treatment strategies. The potential synergy with other anticancer drugs opens new avenues for combination therapies, enhancing cancer management approaches and global health outcomes. All named authors take responsibility for the integrity of the work as a whole and have given final approval for the version to be submitted. E.Q., B.Al-H., A.Al-M., and A.Q. were responsible for writing and designing the study. H.A. and J.C.M. were responsible for designing and implementing the idea, collection of results, and writing the manuscript and drawing the figures. M.A. and M.Al-N. were responsible for writing and designing the study. J.A. and E.A. were responsible for writing and revising the manuscript. M.S., Z.G., Z.T., and X.M. were responsible for the manuscript. All authors reviewed the manuscript. This is a review article and ethical approval is not applicable. Not applicable. # Equal contributions. Article published online: 09 August 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

28 August 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
ZTZhongyuan Tang
Zhongyuan Tang
ZZZonghui Zhang
Zonghui Zhang
JWJiaqi Wang
Jiaqi Wang
ZSZhengwu Sun
Zhengwu Sun
EQEskandar Qaed
Eskandar Qaed
QYQiying Yao
Qiying Yao

7 January 2024 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JWJiaqi Wang
Jiaqi Wang
CMChuchu Ma
Chuchu Ma
ZTZhongyuan Tang
Zhongyuan Tang
ZSZhengwu Sun
Zhengwu Sun
EQEskandar Qaed
Eskandar Qaed
QYQiying Yao
Qiying Yao
Oleanolic acid (3β-hydroxyolean-12-en-28-oic acid, OA) is a kind of pentacyclic triterpene, which widely distributes in nature. OA possesses a powerful anti-cancer effect; however, its low solubility limits its bioavailability and application. In this study, a new OA derivative, K73-03, was used to determine its effect on liver cancer cells and detailed molecular mechanisms. Here, we show that K73-03 may lead to the disorder of mitochondria in HepG2 cells, leading to excessive ROS production and apoptosis in cells. Meanwhile, K73-03 could induce cell apoptosis by inhibiting JAK2/STAT3 pathway and NF-κB/P65 pathway. Collectively, this study may provide a preliminary basis for further cancer treatment of hepatocellular carcinoma.

15 January 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
XXXiaolu Xu
Xiaolu Xu
ZQZitong Qi
Zitong Qi
XHXiumei Han
Xiumei Han
YWYuxing Wang
Yuxing Wang
MYMing Yu
Ming Yu
ZGZhaohong Geng
Zhaohong Geng

1 January 2023 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
XXXiaolu Xu
Xiaolu Xu
ZQZitong Qi
Zitong Qi
DZDawei Zhang
Dawei Zhang
MZMeiwei Zhang
Meiwei Zhang
YRYonggon Ren
Yonggon Ren
ZGZhaohong Geng
Zhaohong Geng
Although computational methods for driver gene identification have progressed rapidly, it is far from the goal of obtaining widely recognized driver genes for all cancer types. The driver gene lists predicted by these methods often lack consistency and stability across different studies or datasets. In addition to analytical performance, some tools may require further improvement regarding operability and system compatibility. Here, we developed a user-friendly R package (DriverGenePathway) integrating MutSigCV and statistical methods to identify cancer driver genes and pathways. The theoretical basis of the MutSigCV program is elaborated and integrated into DriverGenePathway, such as mutation categories discovery based on information entropy. Five methods of hypothesis testing, including the beta-binomial test, Fisher combined p-value test, likelihood ratio test, convolution test, and projection test, are used to identify the minimal core driver genes. Moreover, de novo methods, which can effectively overcome mutational heterogeneity, are introduced to identify driver pathways. Herein, we describe the computational structure and statistical fundamentals of the DriverGenePathway pipeline and demonstrate its performance using eight types of cancer from TCGA. DriverGenePathway correctly confirms many expected driver genes with high overlap with the Cancer Gene Census list and driver pathways associated with cancer development. The DriverGenePathway R package is freely available on GitHub: https://github.com/bioinformatics-xu/DriverGenePathway.